Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:EPRX NASDAQ:FGEN NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.66-2.6%$2.37$1.09▼$7.22$189.32M2.981.03 million shs483,172 shsEPRXEupraxia Pharmaceuticals$5.33-2.6%$5.36$2.20▼$6.20$196.71M1.4912,355 shs5,562 shsFGENFibroGen$12.03-3.2%$9.08$4.50▼$21.94$50.27M0.7651,867 shs13,108 shsTLSATiziana Life Sciences$1.69-5.6%$1.86$0.63▼$2.60$209.16M-0.36301,027 shs655,336 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%-2.21%+13.19%+58.33%-55.67%EPRXEupraxia Pharmaceuticals0.00%-1.11%+0.95%+38.08%+100.38%FGENFibroGen0.00%-0.58%+26.90%+82.34%+21.39%TLSATiziana Life Sciences0.00%+1.81%-15.50%+9.03%+92.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.66-2.6%$2.37$1.09▼$7.22$189.32M2.981.03 million shs483,172 shsEPRXEupraxia Pharmaceuticals$5.33-2.6%$5.36$2.20▼$6.20$196.71M1.4912,355 shs5,562 shsFGENFibroGen$12.03-3.2%$9.08$4.50▼$21.94$50.27M0.7651,867 shs13,108 shsTLSATiziana Life Sciences$1.69-5.6%$1.86$0.63▼$2.60$209.16M-0.36301,027 shs655,336 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics0.00%-2.21%+13.19%+58.33%-55.67%EPRXEupraxia Pharmaceuticals0.00%-1.11%+0.95%+38.08%+100.38%FGENFibroGen0.00%-0.58%+26.90%+82.34%+21.39%TLSATiziana Life Sciences0.00%+1.81%-15.50%+9.03%+92.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.40Hold$8.00200.75% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00106.38% UpsideFGENFibroGen 2.50Moderate Buy$43.00257.44% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FGEN, TLSA, EPRX, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025CCCCC4 TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025CCCCC4 TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.008/22/2025CCCCC4 TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/7/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSpeculative Buy(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$34.24M5.53N/AN/A$3.06 per share0.87EPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AFGENFibroGen$29.62M1.64N/AN/A($50.89) per share-0.24TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)FGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)Latest FGEN, TLSA, EPRX, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 million8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A5.065.06EPRXEupraxia PharmaceuticalsN/A8.728.72FGENFibroGenN/A1.041.02TLSATiziana Life SciencesN/A1.021.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%EPRXEupraxia PharmaceuticalsN/AFGENFibroGen72.71%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%EPRXEupraxia PharmaceuticalsN/AFGENFibroGen3.07%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.17 million64.96 millionOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AFGENFibroGen5704.04 million3.92 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableFGEN, TLSA, EPRX, and CCCC HeadlinesRecent News About These CompaniesTiziana Life Sciences reports CEO purchased 14,848 sharesSeptember 10, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by ChairmanSeptember 5, 2025 | globenewswire.comTiziana Life Sciences Ltd's (NASDAQ:TLSA) largest shareholders are retail investors with 53% ownership, insiders own 43%September 1, 2025 | finance.yahoo.comTiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?August 21, 2025 | marketbeat.comTiziana Life Sciences doses first MSA patient in new trial – ICYMIAugust 15, 2025 | proactiveinvestors.comTiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal ForalumabAugust 14, 2025 | msn.comTiziana Life doses first patient in Phase 2a trial of intranasal foralumabAugust 14, 2025 | msn.comTiziana Life Sciences doses first patient in Phase 2a MSA trialAugust 14, 2025 | proactiveinvestors.comTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System AtrophyAugust 14, 2025 | globenewswire.comTiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDAAugust 11, 2025 | proactiveinvestors.comFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyAugust 11, 2025 | globenewswire.comTiziana Life Sciences reports encouraging results from nasal Alzheimer's treatmentJuly 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's PatientJuly 21, 2025 | globenewswire.comTiziana Life Sciences Ltd (TLSA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comTiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingJune 13, 2025 | seekingalpha.comTiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingJune 13, 2025 | proactiveinvestors.comTiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterJune 13, 2025 | globenewswire.comTiziana Life Sciences to Present at the Bio International ConventionJune 13, 2025 | globenewswire.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, TLSA, EPRX, and CCCC Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.66 -0.07 (-2.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.67 +0.01 (+0.38%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.33 -0.14 (-2.56%) Closing price 09/12/2025 03:49 PM EasternExtended Trading$5.65 +0.32 (+6.00%) As of 09/12/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.FibroGen NASDAQ:FGEN$12.03 -0.40 (-3.22%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.92 -0.12 (-0.96%) As of 09/12/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Tiziana Life Sciences NASDAQ:TLSA$1.69 -0.10 (-5.59%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.67 -0.02 (-1.18%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
